Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 18, 2021updated 26 Oct 2021 7:23am

GenScript and G42 Healthcare partner to explore solutions for Covid-19

GenScript Biotech’s subsidiary GenScript Biotech Singapore has signed an agreement with UAE’s G42 Healthcare for exploring new solutions to fight against Covid-19.

GenScript Biotech’s subsidiary GenScript Biotech Singapore has signed an agreement with UAE’s G42 Healthcare for exploring new solutions to fight against Covid-19.

As part of the deal, the GenScript cPass SARS-CoV-2 neutralisation antibody detection kits will be distributed across 24 locations in the MENA region to assess the effectiveness of vaccines.

This kit detects neutralising antibodies in individuals without using the live SARS-CoV-2 virus.

The conventional method for the measurement of neutralising antibodies in patient samples needs the use of live cells and a high biosafety level environment (BSL3). The results are obtained after several days.

The new cPass antibody detection kit uses pure proteins and can be performed in most standard laboratories in less than an hour.

GenScript noted that the neutralising antibodies represent the first line of defence against the infection by blocking the virus from binding to the host cells, as a result, inhibiting viral propagation.

Content from our partners
The added value of Qarad’s multilingual freephone service to their eIFU solution
Small and simple: how medical device manufacturers select materials
Precision wire: The future of bespoke medical treatment

The cPass kit is said to be the only US FDA Emergency Use Authorized (EUA) serology test for neutralising antibodies from recent and prior infections of the virus.

G42 Healthcare CEO Ashish Koshy said: “Our mission is to provide the definitive, comprehensive and most technologically advanced healthcare solutions in the GCC region.

“Our collaboration with GenScript comes at a time when countries have successfully rolled out national vaccination programs and laboratories can now benefit from rapid detection of the antibodies, thus supporting the healthcare ecosystem.

“Our commitment is to uphold patient health and reinforce our credentials as a trail-blazer in healthcare transformation for the good of all humanity.”

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU